Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
INmune Bio (NASDAQ: INMB) announced the dosing of its first patient in a Phase 2 clinical trial for Quellor™, aimed at treating pulmonary complications from COVID-19. Quellor™ is a selective sTNF inhibitor designed to mitigate the immune response associated with COVID-19 infections. The trial will involve 366 high-risk patients, comparing standard care with Quellor™ administration. Key endpoints include the need for mechanical ventilation and other severe complications. The trial's outcomes could inform further development of Quellor™ and its potential market impact.
INmune Bio (NASDAQ: INMB) reported its Q3 2020 financial results, showing a net loss of approximately $4.7 million, up from $3.1 million in Q3 2019. R&D expenses rose to $2.4 million from $1.2 million, while G&A expenses increased to $2.5 million from $1.9 million. The company received a $2.9 million NIH grant for a Phase 2 study of XPro1595 in treatment-resistant depression and reported a 40.6% decrease in neuroinflammation in Alzheimer’s patients from Phase 1b trials. INMB completed a $25 million stock offering, raising net proceeds of $23.1 million.
INmune Bio, Inc. (NASDAQ: INMB) announced a conference call on November 5, 2020, at 4:30 PM ET to discuss third quarter results for the period ending September 30, 2020, and provide a corporate update. The call will allow stakeholders to gain insights regarding the company’s performance and future outlook. INmune Bio focuses on developing treatments that harness the innate immune system, with clinical trials for products targeting conditions like COVID-19, cancer, Alzheimer's, and depression.
INmune Bio (NASDAQ: INMB) announced new findings from its Phase Ib study targeting neuroinflammation in Alzheimer's patients, presented by CJ Barnum PhD at the International Conference on Alzheimer’s Drug Discovery. Preliminary results indicate that the treatment XPro1595 reduced White Matter Free Water (WMFW) by 40% on average in the arcuate fasciculus, a key brain area for language. The trial is ongoing, focusing on various biomarkers of neuroinflammation. XPro1595 aims to selectively inhibit soluble TNF, which is crucial in neurodegenative diseases.
INmune Bio, a clinical-stage immunology company, announced a Key Opinion Leader (KOL) webinar on treatment resistant depression (TRD) scheduled for September 29, 2020, at 1:00 PM ET. The webinar will cover neuroinflammation's role in TRD, featuring experts Dr. Charles Raison and Dr. John Schneider. Additionally, the company received a $2.9 million SBIR grant from the NIH for a Phase 2 study of its lead candidate, XPro1595, aimed at tackling TRD. Registration for the live webinar is available online.
INmune Bio has secured a $2.9 million Small Business Innovation Research (SBIR) grant from the NIH to support a Phase 2 study of XPro1595, a treatment for treatment-resistant depression (TRD). This randomized, blinded study will involve 100 patients and utilize neuroimaging to explore neuroinflammation's role in TRD. With the study's sites at Emory University and the University of Alabama, the funding will be distributed over the next three years. The findings could have significant implications for treating TRD and related neurodegenerative diseases.
INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology firm, will participate in Oppenheimer's Fall Healthcare Life Science & Med Tech Virtual Investor Summit on September 23, 2020. The management team is open for virtual one-on-one meetings during the event. Interested parties can schedule meetings through a conference representative or contact James Carbonara at James@haydenir.com. The company focuses on harnessing the innate immune system to develop treatments for various diseases, including COVID-19 and cancer.
INmune Bio (NASDAQ: INMB) announced that the European Patent Office has granted a patent for XPro1595, an innovative treatment for neurological disorders, including Alzheimer’s Disease. The patent, effective until 2033 and owned by Xencor, Inc., highlights XPro1595's ability to cross the blood-brain barrier, allowing less invasive peripheral administration. Clinical data suggest a 40.6% reduction in neuroinflammation in key brain regions in Alzheimer’s patients. This patent positions INmune Bio to enhance its development efforts in the European market for CNS disorders.
INmune Bio, Inc. (NASDAQ: INMB) announced a conference call scheduled for August 5, 2020, at 4:30 PM ET to discuss Q2 results for the period ending June 30, 2020. The call aims to provide insights into the company’s ongoing development of treatments targeting the innate immune system, which includes products under the DN-TNF platform and the Natural Killer Cell Priming Platform. These platforms are designed to combat various diseases including COVID-19 complications, cancer, Alzheimer's, and chronic inflammation.
INmune Bio, Inc. (NASDAQ: INMB) was featured on Fox Business News, with CEO Dr. Raymond Tesi discussing the company's planned phase two human trials for a potential COVID-19 treatment using an anti-inflammatory drug. The segment highlighted the company's focus on leveraging the patient’s innate immune system and addressing lower drug costs. INmune Bio is developing several treatments through its DN-TNF and Natural Killer Cell Priming platforms, targeting diseases such as cancer, Alzheimer's, and COVID-19 complications.